257 related articles for article (PubMed ID: 12474988)
1. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
[TBL] [Abstract][Full Text] [Related]
2. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
Arbour N; Rastikerdar E; McCrea E; Lapierre Y; Dörr J; Bar-Or A; Antel JP
Mult Scler; 2005 Dec; 11(6):652-7. PubMed ID: 16320724
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
[TBL] [Abstract][Full Text] [Related]
5. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
[TBL] [Abstract][Full Text] [Related]
7. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor.
Chen M; Valenzuela RM; Dhib-Jalbut S
J Neurol Sci; 2003 Nov; 215(1-2):37-44. PubMed ID: 14568126
[TBL] [Abstract][Full Text] [Related]
9. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.
Dhib-Jalbut S; Chen M; Said A; Zhan M; Johnson KP; Martin R
J Neuroimmunol; 2003 Jul; 140(1-2):163-71. PubMed ID: 12864985
[TBL] [Abstract][Full Text] [Related]
12. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
13. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
14. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
[TBL] [Abstract][Full Text] [Related]
16. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
18. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
